Clinical Trial

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

Study acronym: SPACE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Trial Details
NCT Number NCT06867172
Lead Sponsor Carol Davila University of Medicine and Pharmacy
Conditions Pancreatic Steatosis, Pancreatic Cyst, Pancreatic Adenocarcinoma
Enrollment 66 participants
Start Date 2019-01-01
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-10